Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis

E. Susan Amirian*, Quinn T. Ostrom, Georgina N. Armstrong, Rose K. Lai, Xiangjun Gu, Daniel I. Jacobs, Ali Jalali, Elizabeth B. Claus, Jill S. Barnholtz-Sloan, Dora Il'Yasova, Joellen M. Schildkraut, Francis Ali-Osman, Siegal Sadetzki, Robert B. Jenkins, Daniel H. Lachance, Sara H. Olson, Jonine L. Bernstein, Ryan T. Merrell, Margaret R. Wrensch, Christoffer JohansenRichard S. Houlston, Michael E. Scheurer, Sanjay Shete, Christopher I. Amos, Beatrice Melin, Melissa L. Bondy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10-17), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

Original languageEnglish
Pages (from-to)555-562
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Issue number3
StatePublished - Mar 2019


FundersFunder number
National Institutes of HealthP30CA125123, R01CA139020, P50CA097257, P30CA008748, R01CA52689
National Cancer InstituteR01CA207972
Cancer Prevention and Research Institute of TexasRP160097T
Baylor College of Medicine


    Dive into the research topics of 'Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis'. Together they form a unique fingerprint.

    Cite this